Efficacy and safety of argatroban with or without glycoprotein IIb/IIIa inhibitor in patients with heparin induced thrombocytopenia undergoing percutaneous coronary intervention for acute coronary syndrome

Journal of Thrombosis and Thrombolysis

Volumn 25, Issue 2, 2008, Pages 214-218

  Cruz Gonzalez, Ignacio ^a   Sanchez Ledesma, Maria ^a   Baron, Suzanne J ^a   Healy, Josephine L ^a   Watanabe, Hikari ^b   Osakabe, Masanori ^a   Yeh, Robert W ^c   Jang, Ik Kyung ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acute coronary syndrome; Argatroban; Glycoprotein IIb IIIa inhibitors; Heparin induced thrombocytopenia; Percutaneous coronary intervention

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ARGATROBAN; CLOPIDOGREL; CREATINE KINASE; CREATINE KINASE ISOENZYME; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; TIROFIBAN; TROPONIN T;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANTICOAGULATION; ARTICLE; BOLUS INJECTION; BRAIN HEMORRHAGE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DEATH; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART INFARCTION; HEMATEMESIS; HEMATURIA; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVASCULARIZATION; ST SEGMENT ELEVATION; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; AGED; AGED, 80 AND OVER; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; DRUG THERAPY, COMBINATION; FEMALE; HEPARIN; HUMANS; MALE; MIDDLE AGED; PIPECOLIC ACIDS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA;

EID: 42549130776     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-007-0071-3     Document Type: Article

References (13)

1. Jang IK, Hursting MJ (2005) When heparins promote thrombosis: Review of heparin-induced thrombocytopenia. Circulation 111:2671-2683
2. Lewis BE, Matthai WH Jr., Cohen M, Moses JW, Hursting MJ, Leya F (2002) Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Catheter Cardiovasc Interv 57:177-184
3. Berry CN, Girardot C, Lecoffre C, Lunven C (1994) Effects of the synthetic thrombin inhibitor argatroban on fibrin- or clot-incorporated thrombin: Comparison with heparin and recombinant Hirudin. Thromb Haemost 72:381-386
4. Tricoci P, Peterson ED (2006) The Evolving Role of Glycoprotein IIb/IIIa Inhibitor Therapy in Contemporary Care of Acute Coronary Syndrome Patients. J Interv Cardiol 19:449-455
5. Popma JJ, Berger P, Ohman EM, Harrington RA, Grines C, Weitz JI (2004) Antithrombotic therapy during percutaneous coronary intervention: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126:576S-599S
6. Kong DF, Hasselblad V, Harrington RA, White HD, Tcheng JE, Kandzari DE, Topol EJ, Califf RM (2003) Meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions. Am J Cardiol 92:651-655
7. Alpert JS, Thygesen K, Antman E, Bassand JP (2000) Myocardial infarction redefined-a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 36:959-969
8. Rao AK, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber TL, Bell WR, Knatterud G, Robertson TL, Terrin ML (1988) Thrombolysis in Myocardial Infarction (TIMI) Trial-phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 11:1-11
9. Yeh RW, Jang IK (2006) Argatroban: Update. Am Heart J 151:1131-1138
10. Dang CH, Durkalski VL, Nappi JM (2006) Evaluation of treatment with direct thrombin inhibitors in patients with heparin-induced thrombocytopenia. Pharmacotherapy 26:461-468
11. Jang IK, Lewis BE, Matthai WH Jr., Kleiman NS (2004) Argatroban anticoagulation in conjunction with glycoprotein IIb/IIIa inhibition in patients undergoing percutaneous coronary intervention: An open-label, nonrandomized pilot study. J Thromb Thrombolysis 18:31-37
12. Lincoff AM, Bittl JA, Kleiman NS, Sarembock IJ, Jackman JD, Mehta S, Tannenbaum MA, Niederman AL, Bachinsky WB, Tift-Mann J, 3rd Parker HG, Kereiakes DJ, Harrington RA, Feit F, Maierson ES, Chew DP, Topol EJ (2004) Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial). Am J Cardiol 93:1092-1096
13. Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Kereiakes DJ, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ (2003) Bivalirudin and provisional glycoprotein IIb/ IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 289:853-863